Price
$0.37
Decreased by -0.27%
Dollar volume (20D)
2.28 M
ADR%
10.11
Earnings report date
Nov 7, 2024
Shares float
8.34 M
Shares short
17.31 K [0.21%]
Shares outstanding
8.82 M
Market cap
3.31 M
Beta
0.86
Price/earnings
N/A
20D range
0.35 0.81
50D range
0.35 0.81
200D range
0.35 2.06

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.

It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.

It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.

The company was founded in 2003 and is based in La Jolla, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 8, 24 -0.22
Increased by +77.55%
-0.39
Increased by +43.59%
May 13, 24 -0.55
Increased by +73.56%
-0.90
Increased by +38.89%
Mar 15, 24 -1.37
Increased by +92.49%
-0.87
Decreased by -57.47%
Nov 9, 23 -0.87
Decreased by -17.57%
-1.06
Increased by +17.92%
Aug 11, 23 -0.98
Increased by +79.58%
-2.73
Increased by +64.10%
May 15, 23 -2.08
Decreased by -73.33%
-5.08
Increased by +59.06%
Mar 30, 23 -18.24
Decreased by -102.67%
-28.88
Increased by +36.84%
Nov 14, 22 -0.74
Decreased by -4.23%
-3.20
Increased by +76.88%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 181.80 K
Decreased by -62.93%
-1.97 M
Increased by +11.99%
Decreased by -1.08 K%
Decreased by -137.43%
Mar 31, 24 305.72 K
Decreased by -61.28%
-3.12 M
Decreased by -70.46%
Decreased by -1.02 K%
Decreased by -340.28%
Dec 31, 23 515.03 K
Decreased by -64.07%
-3.50 M
Decreased by -36.56%
Decreased by -680.40%
Decreased by -280.09%
Sep 30, 23 435.38 K
Increased by +55.85%
-2.69 M
Increased by +80.11%
Decreased by -617.75%
Increased by +87.24%
Jun 30, 23 490.47 K
Increased by +136.41%
-2.24 M
Increased by +74.68%
Decreased by -455.88%
Increased by +89.29%
Mar 31, 23 789.63 K
Increased by +30.93%
-1.83 M
Decreased by -162.70%
Decreased by -231.53%
Decreased by -147.89%
Dec 31, 22 1.43 M
Decreased by -12.34%
-2.57 M
Increased by +74.43%
Decreased by -179.01%
Increased by +70.83%
Sep 30, 22 279.35 K
Decreased by -76.74%
-13.52 M
Increased by +21.22%
Decreased by -4.84 K%
Decreased by -238.64%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY